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promoter and enhancer sequences, and the general transcription machinery. Modulation of the concentration and activity of these proteins provides a fundamental mechanism for regulating gene expression. Alterations in the pattern of expression of DNA-binding transcription factors can lead to new programs of gene transcription during development. The modification of the activity of a pre-existing transcription factor represents one of the fastest methods for a cell to alter its pattern of gene expression in response to extracellular stimuli. Furthermore, aberrant transcription factor expression can be associated with oncogenesis. The delineation of the domains responsible for DNA-binding and transcriptional activation provides important clues toward understanding how these factors influence gene expression (Ptashne 1988~ Mitchell and .
The mammalian enhancer-binding protein AP-2 presents an attractive system to study the regulation of transcription factor activity. This protein is controlled at the level of its own gene expression (Williams et al. 1988~ Lfischer et al. 1989 ) and may also be regulated 1Corresponding author. post-translationally {Mitchell et al. 1987) . The AP-2 protein binds to a GC-rich recognition sequence present in the cis-regulatory regions of several viral and cellular genes, including the enhancers of SV40, HTLV-1, human metallothionein IIa, and mouse major histocompatibility complex (MHC} H-2K b (Imagawa et al. 1987~ Mitchell et al. 1987 Nyborg and Dynan 1990} . In addition, AP-2 can stimulate transcription in a binding site-dependent manner both in vivo and in vitro {Mitchell et al. 1987~ Williams et al. 1988 . Interestingly, the expression of AP-2 mRNA and protein is stimulated by retinoic acid-induced differentiation of human NT2 teratocarcinoma cells {Williams et al. 1988~ Ltischer et al. 1989} . Furthermore, AP-2 is expressed in a cell-type-specific manner~ AP-2 is absent in the human hepatoma cell line HepG2 but present in human HeLa fibroblast cells (Williams et al. 1988} . More recent data also show that AP-2 mRNA levels are regulated both temporally and spatially during mouse embryogenesis (Mitchell et al. 1991} . Intriguingly, the highest levels of expression appear to correspond to early neural crest cells and suggest that AP-2 plays a role in their subsequent differentiation and development.
The activity of the AP-2 protein also appears to be controlled post-translationally by both positive and neg-ative regulatory mechanisms. Several studies suggest that AP-2 is displaced from its recognition site by competition from adjacent DNA-binding proteins (Isra61 et al. 1989; Mercurio and Karin 1989; Courtois et al. 1990 ). The DNA-binding activity of AP-2 can also be blocked by the SV40 large T antigen oncogene product (Mitchell et al. 1987) . In contrast, the ability of AP-2 to activate gene expression is stimulated by the hepatitis B virus X protein (Seto et al. 1990 ). The AP-2 DNA recognition sequence also seems to act as both a TPA-and cAMPinducible element (Imagawa et al. 1987; Roesler et al. 1988) .
The examination of AP-2 activity has been facilitated by the recent cloning of a human cDNA encoding the entire AP-2 open reading frame (Williams et al. 1988 ).
Expression of the full-length clone in Escherichia coli generated a protein that was indistinguishable from the endogenous HeLa factor in its ability to bind DNA and activate transcription. Here, we report the analysis of the DNA-binding and transcriptional activation properties of the AP-2 protein using a series of cDNA mutants. This analysis reveals that AP-2 has a modular organization with separate domains involved in transcriptional activation and DNA binding/dimerization. The information obtained should enable us to dissect the mechanism of AP-2 action and understand how it may be regulated.
Results

The AP-2 recognition sequence contains a dyad repeat
The AP-2 protein must perform a minimum of two functions to act as a sequence-specific DNA-binding transcription factor. First, AP-2 must be able to recognize and bind to a specific DNA sequence; second, the protein must recruit the general transcription machinery to increase the rate of initiation. To analyze the former process we have examined which components of the AP-2 recognition sequence are important for specific protein/ DNA contact. Previously, DNase I footprinting experiments have shown that AP-2 binds to a GC-rich sequence that is present in a variety of promoter and enhancer elements associated with both viral and cellular genes (Imagawa et al. 1987; Mitchell et al. 1987) . However, DNase I footprinting does not generate information concerning the contribution of individual nucleotides within the DNA-binding site. Therefore, to obtain a more detailed understanding of AP-2 DNA binding, we performed a series of methylation interference assays using the AP-2 sites present in the SV40 enhancer and the human metallothionein IIa distal basal level element (hMtIIa BLE). Methylation interference assesses the steric inhibition of DNA binding caused by the presence of an additional methyl group on guanine and adenine residues. In this procedure a DNA template was partially methylated and used for electrophoretic mobility-shift assays (EMSA) with AP-2 protein. Subsequently, the bound and free probes were isolated, cleaved with piperidine, and analyzed on a denaturing polyacrylamide gel. The results of the methylation interference experiments are summarized in Figure 1A . These studies reveal the occurrence of a consensus sequence, 5'-GN4GGG-3', present on one strand of both the SV40 and hMtIIa-binding sites. Furthermore, a slightly degenerate copy of this sequence also occurs on the two complementary strands. Thus, the AP-2-binding site appears to contain a dyad repeat. Methylation of the guanine present at the center of the dyad repeat does not affect AP-2 DNA binding. In contrast, methylation of the flanking guanines present in the 5'-GN4GGG-3' sequence reduces AP-2 binding to these sites.
To determine the contribution of all the individual bases within and around the binding sites we also performed missing contact probing assays. This procedure is used to determine how the removal of a particular base from the recognition site affects DNA binding. The experimental protocol was similar to methylation interference except that the starting DNA template was partially depurinated or depyrimidinated. Representative results obtained from this analysis are shown in Figure 1B , and the data are summarized schematically in Figure 1C . The data indicate that many bases within both the SV40 and hMtIIa sequences are needed to generate a functional AP-2 binding site. In addition, missing contact probing of the SV40 AP-2-site illustrates that flanking DNA sequences may also be important in the generation of a functional binding site. Interestingly, however, the removal of symmetrically located cytosine bases within the binding site does not affect AP-2 DNA binding (SV40 base pairs 233 and 237; hMtIIa base pairs -177 and -173). Similarly, the cytosine present at the center of dyad symmetry is not important for protein/DNA contact. Molecular modeling indicates that these three cytosine bases can all be aligned on one face of the DNA helix and suggests that AP-2 is not contacting this region of the DNA (Fig. 1D) . It is also interesting to note that the missing contact probing and methylation interference procedures measure different aspects of DNA binding, as AP-2 can bind to the recognition sequence when the guanine at the center of dyad symmetry is methylated but not when it is removed. Taken together, the results show that the SV40 and hMtIIa sites share several common sequence features. Moreover, the data allow the identification of a palindromic sequence, 5'-GCCN3-GGC-3', which appears to form the core recognition element for the AP-2-binding site.
The carboxy-terminal region of the AP-2 protein mediates DNA binding
The determination of which nucleotides in the recognition site are involved in AP-2 DNA binding represents one aspect in the analysis of protein-DNA interaction. We then characterized which regions of the AP-2 peptide sequence were responsible for DNA binding. In this analysis mutant AP-2 polypeptides were synthesized by in vitro translation and assayed for their ability to bind an AP-2 site using EMSA. The results obtained, by using a series of amino-and carboxy-terminal deletion mutants, are illustrated in Figure 2A . Removal of the most amino- terminal 165 amino acids of AP-2 does not affect sequence-specific DNA binding to an oligonucleotide containing an AP-2 site (mutants AN30 to AN165). However, further deletion of the adjacent amino-terminal 62 amino acids completely abolishes DNA binding (AN227). The carboxy-terminal boundary of this DNAbinding domain is located within 50 amino acids of the carboxyl terminus of the protein (AC390). Analysis of the expression levels of the various deletion mutants indicates that they were all produced in comparable amounts (data not shown). Furthermore, these results were confirmed by DNase I footprinting, using bacterially expressed protein (data not shown). This analysis of the DNA-binding domain was refined by using further amino-and carboxy-terminal deletion mutants, and the data obtained are summarized in Figure 2B . The carboxyterminal boundary of the AP-2 DNA-binding domain is well defined. Removal of the last 28 amino acids of the protein has no effect on DNA binding (AC409), whereas deletion of the next 19 residues abolishes this potential (AC390). Similarly, the mutants AN203 and AN227, which are capable and incapable of binding DNA, respectively, place the amino-terminal boundary of the DNAbinding region between amino acids 204 and 227. Therefore, the region of AP-2 that confers sequence-specific DNA binding resides in a stretch of -2 0 0 amino acids located toward the carboxyl terminus of the protein.
Analysis of the sequence reveals that the first half of this region contains an abundance of basic residues, whereas the latter half is potentially a-helical in nature.
The DNA-binding region contains a dimerization domain
The finding that AP-2 binds to a palindromic recognition sequence implies that AP-2 may interact with DNA as a The ability of the protein to bind DNA in a sequence-specific manner, as determined by EMSA and DNase I footprinting, is summarized by + or -symbols, which refer to wild-type or undetectable binding, respectively. Dimerization refers to the potential of amino-terminal deletions to associate with the wild-type protein or the carboxy-terminal deletions to dimerize with AN165. (n.d.) Not done.
multimer. Moreover, the region of AP-2 required for D N A binding is quite large and suggests that, in addition to direct D N A contact, some auxiliary function m a y help stabilize the protein-DNA interaction, such as protein-protein contact between AP-2 molecules. Therefore, we have examined the ability of AP-2 to multimerize using EMSA (Fig. 3A) . The in vitro-translated wildtype AP-2 protein produces a protein-DNA complex of slow mobility, whereas the AN165 deletion m u t a n t yields a faster migrating species. When these two proteins are cotranslated an intermediate band is produced, indicating the presence of a heteromeric complex. The absence of any intermediate band when the wild-type and AN165 mutant are mixed after separate translation demonstrates that there are not simply two independent binding sites on this DNA template. In addition it also shows that the m u l t i m e r is relatively stable, as there is no obvious exchange between the wild-type and m u t a n t complexes during the binding reaction. Further experiments indicate that the half-life of the heteromer exceeds 5 hr (data not shown). The EMSA experiment demonstrates that AP-2 binds to D N A as a stable multimer, but it does not directly address the nature of AP-2 in solution. For this purpose we performed glutaraldehyde cross-linking experiments in the absence of DNA. The wild-type protein was translated in vitro in the presence of [3SS]methionine and partially purified by sequence-specific D N A affinity chromatography. Following cross-linking, the proteins were resolved by SDS-PAGE and visualized by autoradiography. Figure 3B shows that the 50-kD wild-type protein yields products of -1 0 0 kD in the presence of glutaraldehyde, indicating that the protein exists as a dimer in solution. Similarly, the 30-kD AN165 polypeptide generates a 60-kD dimeric species upon cross-linking. In an analogous experiment to the EMSA shown in Figure 3A ,
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Cold Spring Harbor Laboratory Press on June 24, 2017 -Published by genesdev.cshlp.org Downloaded from the two proteins were also either cotranslated or mixed after separate translation. When the proteins are mixed and cross-linked only the 60-kD mutant dimer and the 100-kD wild-type dimer are generated. In contrast, an additional 80-kD dimeric complex is also formed by the wild-type and AN165 proteins when they are cotranslated. This indicates that the appearance of dimers is not simply a random cross-linking event but a specific protein-protein interaction that occurs in the absence of DNA. Furthermore, because the ~N165 mutant represents approximately the minimum polypeptide required for DNA contact, the EMSA and cross-linking data indicate that the domain responsible for dimerization is part of the DNA-binding region.
To further localize the dimerization domain we have utilized a coimmunoprecipitation assay. This method enables complex formation to be studied in mutants that are incapable of binding to DNA. Antiserum directed against an amino-terminal polypeptide will recognize the wild-type protein but not amino-terminal deletion mutants ( Fig. 4AI . However, if these mutants can dimerize with the wild-type protein they will be purified by coimmunoprecipitation. Figure 4A illustrates that the AN165 mutant is only immunoprecipitated when it is cotranslated with the wild-type protein, again indicating that it is capable of forming a stable dimer in the absence of DNA. Moreover, the AN278 polypeptide can also stably associate with the wild type {Fig. 4A}, even though it is unable to bind to DNA. However, deletion of the amino-terminal 306 amino acids of the protein abolishes the ability of the polypeptide to associate with the wild type, indicating that a domain important for complex formation has been destroyed. A similar set of experiments were performed with a series of carboxy-terminal deletion mutants. However, because the wild-type and carboxy-terminal deletions of interest were of similar size, it was simpler to determine whether the mutant proteins could associate with the shorter AN165. Figure  4B shows the results obtained when an antiserum raised against an amino-terminal peptide was used to precipitate the carboxy-terminal deletions and any associated A165. In common with the wild type, the AC409 mutant is capable of dimerizing with the AN165 protein when they are cotranslated but not mixed. In contrast, the AC390 mutant has lost the ability to complex with the AN165 protein. These data were also confirmed by glu- taraldehyde cross-linking studies (data not shown), and the results from these and other mutants are summarized schematically in Figure 2B . All of the proteins that can interact with DNA occur as stable dimers in solution. In addition, all of the proteins that do not dimerize have lost the ability to bind DNA. This strongly suggests that dimerization is a prerequisite for AP-2 DNA binding. Interestingly, two mutants that have lost the ability to bind DNA are still capable of dimerizing (AN227 and AN278). Therefore, the sequences responsible for dimerization are situated between amino acids 278 and 409. These results indicate that the dimerization domain forms an integral part of the DNA-binding region.
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A short proline-rich sequence mediates AP-2 transcriptional activation
The 50-kD AP-2 protein possesses a minimum of two functions, namely DNA binding and transcriptional activation. It was possible that these two properties exist in separate domains of the molecule (Ptashne 1988; Mitchell and Tjian 1989) or, alternatively, that they were intimately linked together (Hochschild et al. 1983; Hollenberg et al. 1987; Miesfeld et al. 1987) . To ascertain which AP-2 sequences were responsible for transcriptional activation we performed cotransfection experiments. Previously, Drosophila Schneider cells were used as an in vivo complementation system to assay for AP-2 transcriptional activation (Williams et al. 1988 ). However, it would also be useful to assess the ability of AP-2 to stimulate gene expression in mammalian systems. We chose to test the transcriptional properties of cotransfected AP-2 in the human hepatoma cell line HepG2, which lacks endogenous AP-2 mRNA and protein (Williams et al. 1988 ). The AP-2-coding region was introduced into these cells under the control of the Rous sarcoma virus long terminal repeat (RSV LTR) in the expression vector SPRSV-AP2 (Fig. 5C ). The reporter construct used in these experiments, termed A2BCAT (Fig. 5B) , contains a triplicated AP-2-binding site placed upstream of the adenovirus E1G TATA box. Figure 5A shows that the A2BCAT reporter plasmid has a very low basal• level of CAT activity that is greatly stimulated by the addition of cotransfected AP-2. In contrast, AP-2 has no effect on the BCAT plasmid lacking the AP-2-binding sites. This result demonstrates that AP-2 is capable of activating gene expression in a binding site-dependent manner in vivo in mammalian cells.
The availability of these expression and reporter plasmids now enabled the regions of AP-2 responsible for transcriptional activation to be localized. A series of 5', 3', and internal deletion mutants were inserted into the SPRSV expression vector and tested in the HepG2 cell cotransfection assay. Figure 6 provides a schematic summary of the results obtained with these mutants. The amino-terminal deletions indicate that removal of 14 amino acids between residues 51 and 65 severely reduces trans-activation by AP-2 (AN51 and AN65). Furthermore, the ability of the protein to stimulate gene expression is abolished by deletion of the next 12 amino acids (AN77). More extensive deletions toward the carboxyl terminus are also inactive (data not shown). In addition, the major importance of amino acids 31-77 is confirmed by the internal deletion INT 31/77, which makes the protein inactive in this assay. Interestingly, examination of this region of the protein reveals a sequence unusually rich in proline residues (30%; see Fig. 8C, below) .
The internal deletions also indicate that other regions of the protein may contribute to trans-activation by AP- The NcoI site (Nco) at the 5' end of the open reading frame, the EcoRI {R1) site at the 3' end of the AP-2 sequences, and the XhoI site (X) used for cloning are indicated. All nucleotide numbers are given with respect to the sequence of AP2-9 (Williams et al. 1988 ).
2. In particular, a deletion of 48 amino acids, which removes a region of net acidic charge, reduces stimulation of gene expression fourfold (INT 123/171). As expected, carboxy-terminal deletions that impinge on the DNAbinding domain fail to activate transcription (AC390). Taken together, these data indicate that transcriptional activation by AP-2 relies on at least two distinct parts of the protein, the carboxy-terminal DNA-binding domain and an amino-terminal proline-rich sequence. However, the relative activity of the protein is also disrupted by a series of intemal deletions. This suggests that several regions of the protein may need to interact correctly to generate a functional AP-2 molecule. Indeed, the in vivo cotransfection assay actually measures the sum of a number of parameters, including protein stability, nuclear localization, and ability to activate transcription. To examine some of these possibilities we have determined whether the proteins are correctly expressed and localized in vivo. Nuclear and cytoplasmic extracts were prepared from transfected HepG2 cells, and the presence of AP-2 derivatives was determined by immunoblotting (data not shown). The data indicated that the wild-type and mutant constructs containing an intact DNA-binding domain were all expressed and translocated to the nucleus.
The AP-2 proline-rich region activates gene expression when linked to the GAL4 DNA-binding domain
An altemative method in determining whether a particular region of AP-2 is capable of activating gene expression is to link it to a heterologous DNA-binding domain. The well-characterized yeast GAL4 DNA-binding protein provides a useful recipient for this type of assay because there is no endogenous GAL4-1ike activity in m a m m a l i a n cells {Ptashne 1988). Therefore, the 147-amino-acid GAL4 DNA-binding domain was attached amino-terminal to several AP-2 polypeptides, and the activating potential of the chimeric constructs was tested by cotransfecting them with a GAL4 reporter construct. Figure 7 summarizes the data obtained when various GAL4/AP-2 fusions were cotransfected into HepG2 cells with the G5BCAT reporter construct, which contains five GAL4-binding sites upstream of the adenovirus E1B
TATA box {Lillie and Green 1989).
The GAL4 DNA-binding domain alone was unable to activate CAT expression in this assay ( Fig. 7 ; Ptashne 1988). However, when the proline-rich region of AP-2 was attached to GAL4 [GAL4 + 6/77}, the resulting fusion could potently activate expression, consistent with the observation that this region was the most important single component in the context of AP-2 itself. Furthermore, the inclusion of the adjacent carboxy-terminal 40 amino acids leads to an approximately fourfold increase in transactivation {GAL4 + 6/117). This sequence produces a similar effect on the activating properties of wild-type AP-2 ( Fig. 5; INT 77/117) and also contains a high concentration of prolines (see Fig. 8C ). Addition of the adjoining acidic region to the proline-rich sequence does not augment expression further {GAL4 +6/165}, and this acidic region alone produces only a mild stimulation of gene expression (GAL4 + 117/165}. Intriguingly, the fusion of essentially wild-type AP-2 to the GAL4 sites deviate from this consensus. Interestingly, the missing contact probing studies also indicate that AP-2 relies on many bases to stabilize the protein-DNA interaction, and the majority of these nucleotides seem to occur on one side of the DNA helix. However, it is unlikely that AP-2 relies solely on contacts with bases to achieve DNA binding, and preliminary ethylation interference experiments suggest that AP-2 may also interact with the phosphate backbone IT. Williams, unpubl.) . These studies will help in determining a more accurate structural model of the interactions of the AP-2 protein with its DNA recognition sequence.
Concomitant with the analysis of the nucleotide sequences involved in AP-2 DNA recognition, we have determined which regions of the AP-2 protein constitute the DNA-binding domain. A region of -200 amino acids, located toward the carboxyl terminus of AP-2, is sufficient to produce sequence-specific DNA binding. Our analysis also demonstrates that AP-2 binds to DNA as a dimer, consistent with the dyad symmetry present in the AP-2-binding site. The AP-2 protein also occurs as a dimer in solution. Interestingly, all of the AP-2 deletion mutants that bind to DNA can dimerize, whereas the mutants that do not dimerize have also lost their DNAbinding potential. Therefore, dimer formation is apparently an essential requirement for AP-2 protein-DNA interaction, and the dimerization domain forms an integral component of the DNA-binding region. Examination of the amino acid sequence reveals that the aminoterminal haft of the DNA-binding region has an abundance of basic residues. In contrast, the latter half of this region, which corresponds to the dimerization domain, is potentially et-helical in nature. Therefore, one might predict that the basic region will directly contact the DNA, while the dimerization domain stabilizes this protein-DNA contact by a protein-protein interaction. Alternatively, the region involved in dimerization might also contain some residues participating directly in DNA binding. The AP-2 DNA-binding sequences do not resemble those from other transcription factors, such as the homeo box, zinc fingers, or HMG box (Evans and Hollenberg 1988~ Herr et al. 1988~ Hoey and Levine 1988~ Jantzen et al. 1990 ). Interestingly, though, the overall organization of the AP-2 DNA-binding domain is reminiscent of the bZIP and HLH proteins, where a basic region in association with an adjacent dimerization domain mediates stable DNA contact (Landschulz et al. 1989~ Murre et al. 1989~ Jones 1990} . However, the dimerization domain of AP-2 does not contain a leucine repeat, nor does it share any homology with the HLH motif. The sequences responsible for AP-2 dimerization are approximately twice the length of these other domains. A number of internal deletions in the AP-2 dimerization domain suggest that it possesses a novel design that we term a helix-span-helix {HSH) structure {Williams and Tjian 1991}. The presence of a dimerization domain also raises the intriguing possibility that the activity of AP-2 may be regulated by association with other proteins possessing this HSH motif. This type of mechanism provides an important method to control the activities of many bZIP and HLH proteins, including cjun and myoD {Benezra et al. 1990~ Garrell and Modolell 1990~ Jones 19901 .
The number of sequence motifs that have been classified as DNA-binding domains continues to expand as more transcription factors are analyzed. Recently, novel DNA-binding sequences have been identified in several factors, including CTF/NF1 (Mermod et al. 19891 and SRF (Norman et al. 1988} . The extended DNA-binding domain of AP-2, which occupies half of the protein, also appears to represent a new type of structure. However, it is possible that the tertiary structure of several of these proteins may be similar. In this context it is worth noting that AP-2 contains a stretch of amino acids with weak sequence similarity to a bacterial DNA-binding protein, NodD {Fig. 8B; Appelbaum et al. 1988} .
A number of studies indicate that the AP-2 DNA-binding site is an important component of several upstream regulatory regions Hyman et al. 1989}. However, conflicting data exist conceming the relative importance of the AP-2 site when it is isolated from other cis-regulatory elements in minimal promoter constructs. The AP-2 protein is able to activate gene expression in an in vitro-reconstituted transcription system derived from HeLa cells (Mitchell et al. 1987) . Furthermore, Imagawa et al. (1987) reported that the AP-2-binding site could act as an inducible enhancer element in vivo in HeLa cells. In contrast, Kanno et al. (1989) observed that the AP-2 site did not produce any transcriptional stimulation in these cells. Potentially, this disparity could simply reflect the different context of the AP-2 DNA-binding sites in these reporter constructs.
Here, we have shown that the AP-2 DNA-binding site can function as a cis-regulatory element in vivo in mammalian HepG2 cells. Consistent with the observation that AP-2 is normally absent from these HepG2 cells (Williams et al. 1988) , the presence of several AP-2-binding sites does not alter the level of expression from a minimal promoter construct. The subsequent addition of exogenous AP-2 by transfection leads to a 5-to 10-fold binding site-dependent increase in expression. These experiments have also been extended to HeLa cells, which already possess endogenous AP-2 protein. Interestingly, we observed that the presence of AP-2 sites in our reporter construct did not increase the basal level expression obtained with the minimal BCAT plasmid. Moreover, the addition of the AP-2 expression plasmid into the HeLa cells caused a significant binding site-dependent increase of promoter activity (data not shown). Therefore, AP-2 can also function as a transcription factor in vivo in HeLa cells. However, it appears that the endogenous AP-2 in HeLa cells is unable to stimulate transcription from a transfected reporter plasmid containing AP-2 sites. One possible explanation for this observation is that the amount of AP-2 in these cells is below a threshold level for activation. Such a threshold could simply reflect low amounts of AP-2 in HeLa cells, where it might be unable to compete with other proteins for DNA and the general transcriptional machinery. A1-tematively, it is possible that the activity of endogenous AP-2 is under negative control, a process that has been observed for several transcription factors including c-jun and NFKB (Baeuerle and Baltimore 1988; Baichwal and Tjian 1990) . For both of these altematives a rise in the level of AP-2 protein resulting from transfection could overcome this threshold. An increase in transcription from an AP-2 reporter construct is observed in NT2 teratocarcinoma cells following retinoic acid-induced differentiation, which raises the levels of AP-2 protein in these cells (Ltischer et al. 1989) . Therefore, one would predict that AP-2 might function as a more potent transcriptiofial activator in cells of the neural crest lineage where it is expressed in high levels (Mitchell et al. 1991 ).
We have transfected mutant AP-2 cDNA constructs into HepG2 cells to delineate the sequences necessary for transcriptional activation. The major activation domain of AP-2 occupies a region of -80 amino acids near the amino terminus of the protein (Fig. 8) . This region also stimulates gene expression when attached carboxyterminal to the DNA-binding domain of the GAL4 protein. The most distinguishing feature of the activation domain is the high content of proline residues, which constitute 30% of the amino acid sequence in the most important part of this region (Fig. 8C) . In this respect AP-2 resembles the transcription factors CTF/NF1 and OTF-2, which also contain proline-rich activation domains (Mermod et al. 1989; Gerster et al. 1990 ). Therefore, the proline residues present in these domains may provide the essential link to the RNA polymerase II transcriptional machinery. Altematively, it is possible that the prolines could form a rigid structural framework that enables other critical residues to interact with the general factors. However, there is no obvious further similarity between the activating sequences of AP-2 and CTF/NF1 proteins. Indeed, a notable feature of the AP-2 activation domain is that it contains several aromatic amino acids (Y, F, W), which appear to be critical in some activation domains but do not occur in the activating region of certain forms of CTF/NF1 (Mermod et al. 1989; Cress and Triezenberg 1991) , Interestingly, examination of the AP-2 activating sequence (Fig. 8C ) reveals one long overlapping repeat (FQPPYFP/FPPPYQP) and one short repeat (DPYS/DPYS), which might indicate some reiterated structural motif. Moreover, a sequence similar to the longer of these repeats is also present at the carboxyl terminus of the OTF-2 proline-rich transcriptional activation domain (PAPYQP) (Gerster et al. 1990) .
A number of amino acid motifs have been defined as transcriptional activators, including acidic, glutaminerich, and proline-rich sequences. Recent data suggest that these activation motifs may use different mechanisms to interact with the general transcriptional machinery. In particular, the proline-rich CTF/NF1 protein appears to require a different set of coactivator molecules to mediate its interaction with TFIID and the other general factors than proteins containing acidic or glutaminerich activation domains (Pugh and Tjian 1990) . It will be interesting to determine whether the AP-2 protein is distinct from these other transcription factors or whether it functions by the same process as CTF/NF1.
In conclusion, our results demonstrate that AP-2 has a modular design and is composed of distinct domains involved in transcriptional activation and DNA binding/ dimerization. The cDNA mutants generated in this study also provide the necessary reagents to determine which regions of AP-2 are the targets of positive and negative regulation by other factors. Furthermore, it is possible that some mutants will act as dominant negative suppressors of endogenous AP-2. Therefore, the AP-2 protein may represent a useful tool in determining how the control of transcription factor activity affects gene expression and developmental regulation.
Materials and methods
Plasmid constructs for in vitro transcription
The AP-2 vectors used for in vitro transcription and cotransfection were derived from AP-2 linker. This plasmid was made by fusing an oligonucleotide (5'-CATGG TTTGG AAATT GAC-GGATAATATCAA GT-3'; nucleotides 62-93) to an RsaIHindIII fragment of AP2-9 (nucleotide 94, through the EcoRI site at nucleotide 1636, into the polylinker; Williams et al. 1988) , and ligating this fusion into NcoI-HindIII-cleaved pKK233-2 (Pharmacia). This creates an NcoI site at the translational start of AP-2 and causes a conservative change of the second amino acid from leucine to valine. An oligonucleotide (5'-ATCAG GCCTG ATTGA CTGAC TCGAG GGATC CA-3') was then inserted into the 3' polylinker, between the EcoRV and HindiiI sites. This reforms the EcoRV and HindIII sites and introduces stop codons in all three frames. A StuI site is also present 5' to the stop codons, and an XhoI and BamHI site occurs to the 3' side.
To generate 3' deletion mutants, fragments of AP-2 linker, from the NcoI site at nucleotide 62 to either the FnuDII site at nucleotide 1230 (AC390), or a T4 DNA polymerase-repaired NcoI site at nucleotide 1289 (aC409), were ligated into NcoIEcoRV-restricted AP-2 linker, aC413 was made by ligating an AP-2 fragment from the NcoI site at nucleotide 62 to the RsaI site at nucleotide 1299 into NcoI-StuI-restricted AP-2 linker. For 5' deletion mutants, NcoI linkers were added to the 5' ends of AP-2 restriction fragments, which terminated at their 3' ends at the XhoI site of AP-2 linker. These fragments were then ligated into NcoI-XhoI-restricted AP-2 linker. The appropriate AP-2 open reading frame was maintained by using either an 8-met, 10-mer, or 12-met NcoI linker (Pharmacia). The 5' ends of the relevant restriction fragments are PvuII at nucleotide 153 (AN30), HindII at nucleotide 291 (AN77), PvuII at nucleotide 414 (ANll7), SmaI at nucleotide 557 (AN165), RsaI at nucleotide 742 (aN227), T4 DNA polymerase-repaired BglII at nudeotide 853 (AN263), T4 DNA polymerase-repaired PstI at nucleotide 896 (AN278), and RsaI at nucleotide 979 (AN306).
The AP-2-coding sequences, from the NcoI site at nucleotide 62 to the XhoI site in the 3' polylinker, were ligated into NcoISalI-restricted pl3Sal (Norman et al. 1988 ), generating pBSal AP-2 wild type. The various deletions were constructed in a similar manner. The plasmid pl3Sal AN203 was made from pl3Sal AP-2 wild type, using a 5' oligonucleotide 5'-GG CAG CCC ATG GTG GTG AAC CCC AAC G-3' (which has sequence identity to nucleotides 672-686) for polymerase chain reaction (PCR) in conjunction with a 3' oligonucleotide 5'-GGA TCG AAT TCC TCA CTT TCT GTG CTT CTC CTC TTT GTC-5' (which is complementary to nucleotides 1378-1350). The PCR product was restricted with NcoI and ligated into NcoI-digested pl3Sal AP-2 wild type, and a plasmid containing the correct orientation was identified. All AP-2 nucleotide numbers are given with reference to AP2-9 (Williams et al. 1988) .
In vitro transcription~translation and EMSAs
The AP-2 pBSal derivative plasmids were linearized 3' to the coding region with XbaI and transcribed in vitro by using T7 RNA polymerase {Stratagene). The RNA was translated in nuclease-treated rabbit reticulocyte lysate (Promega) in the presence of [aSS]methionine, followed by RNase A treatment as recommended by the manufacturer. Different AP-2 polypeptides were only "mixed" following this RNase A treatment to ensure that cotranslation could not occur. EMSA was performed essentially as described (Ausubel et al. 1989) . Briefly, 2.5 txl of reticulocyte lysate was incubated in a buffer containing 10 mM Tris-C1 (pH 7.9), 4.5% Ficoll 400, 60 mM KC1, 4 mM MgC12, 0.1 mM EDTA, 50 txg/ml of BSA, 0.2% NP-40, and 40 ng/~l of poly[d(I-C)] for 10 rain on ice before the addition of a2P-end-labeled double-stranded AP-2 oligonucleotide (10,000 cpm). Binding reactions were allowed to proceed for an additional 15 rain on ice and were fractionated on pre-electrophoresed 15 cm 4% (40 : 1) polyacrylamide/0.25 x TAE gels containing 0.5% NP-40, at 4°C. For analysis of heterodimer formation, 36-cm gels were used. Gels were dried and exposed through two pieces of blank X-ray film to attenuate the ass label and record only the a2p signal. The AP-2 oligonucleotide was derived from hMtIIa (Williams et al. 1988) . Autoradiography and Western blotting analysis of SDS-PAGE indicated that equivalent amounts of all proteins were made (data not shown).
DNA methylation and missing contact interference analyses
Experiments were performed essentially as described (Ausubel et al. 1989) . Briefly, 20 I~1 of reticulocyte lysate containing AP-2 protein derived from pBSal AP-2 wild type was incubated with 2 x l0 s cpm of modified probe in a scaled-up EMSA DNA-binding reaction. Following electrophoresis, the DNA was transferred to NA45 paper (Schleicher and Schuell) in EMSA gel running buffer at 4°C for 60 rain. The parts of the membrane corresponding to the bound and free probe were removed and analyzed as described by Singh et al. (1988) . Autoradiograms of the sequencing ladders were quantitated using a Hoefer GS300 densitometer. The AP-2 oligonucleotides were derived from SV40 (Mitchell et al. 1987 ) and hMtIIa (Williams et al. 1988 ). Single-stranded oligonucleotides were a2P-end-labeled with polynucleotide kinase on either the top or bottom strand, annealed with the unlabeled complementary strand, and purified on an 8% acrylamide gel. The probes were methylated, depurinated, or depyrimidinated according to the procedure of Maxam and Gilbert (1980) .
Cross-linking
AP-2 proteins, made by in vitro translation in the presence of [aSS]methionine, were purified by DNA affinity chromatography using an AP-2 oligonucleotide derived from hMtIia (Williams et al. 1988 ). Proteins were cross-linked with 0.001% glutaraldehyde for 60 rain at room temperature and analyzed as described by Turner and Tjian {1989).
Coimmunoprecipitation
The AP-2 proteins, made by in vitro translation in the presence of [3SS]methionine, were immunoprecipitated using an affinitypurified antisera specific for the amino terminus of AP-2 (Lfischer et al. 1989) . Immunoprecipitation was performed in RIPA buffer (150 mM NaC1, 10 mM Tris-C1 at pH 7.4, 1% Triton X-100, 1% sodium deoxycholate, 1 mM EDTA, 1 mM PMSF, and 2 lxg/ml aprotinin) using protein A-Sepharose (Pharmacia) essentially as described (Ausubel et al. 1989 ). Proteins were separated by SDS-PAGE and visualized by fluorography following treatment of the gel with Amplify (Amersham).
Plasmid constructs for transfection
The reporter constructs, BCAT containing the Elb TATA box, and G5BCAT, which also contains five GAL4-binding sites, have been described previously (Lillie and Green 1989) . A2BCAT was made by inserting three copies of the sequence 5'-CTGAC CGCCC GCGGC CCGT-3', corresponding to nucleotides -185 to -167 of the hMtIIa distal BLE, into the Sa/I site of BCAT. All three AP-2 sites are oriented toward the TATA box. Similar results are obtained if the three AP-2 sites are inserted in the opposite orientation (data not shown).
The mammalian expression vector SPRSV was derived from RSV-2 (generous gift of C. Gorman), by inserting an 8-met NcoI linker (GCCATGGC) into the SmaI site of the polylinker. The NdeI-PvuII fragment, spanning the RSV LTR, the polylinker, and the SV40 poly(A) signal, was then inserted into NdeIEcoRV-restricted pSP72 (Promega), generating SPRSV. The wild-type AP-2 vector, SPRSV-AP2, was made by ligating a fragment of AP-2 linker, from the NcoI site at nucleotide 62 to the XhoI site in the 3' polylinker, into NcoI-XhoI-restricted SPRSV. Similarly, SPRSV AN77, &C413, and AC390 were made from their pKK derivatives. SPRSV ANS1 was made by ligating an oligonucleotide 5'-CATGG CCGAC TTCCA GCCCC CATAC TTCCC CCCAC CCTAC CAGCC TATCT ACCCC CAGTC GCAAG ATGCT TACTC CCACG TC-3' to SPRSV-AP2 lacking an NcoI-HindII fragment (nucleotides 62-290). Similarly, SPRSV AN65 was made using an oligonucleotide 5'-CATGG CCATC TACCC CCAGT CGCAA GATCC TTACT CCCAC GTC-3'. The GAL4/AP-2 plasmids were based on pSG424 (Sadowski and Ptashne 1989) , which encodes amino acids 1-147 of GAL4. The fusions were made by ligating fragments of AP-2 into the SmaI site 3' to the GAL4-coding sequences; GAL4 + 6/165 is a HpaI-SmaI fragment (nucleotides 77-556) from pAP2L (Williams et al. 1988 ); GAL4 + 6/117 is a HpaI-PvuII fragment from pAP2L (nucleotides 77-413); GAL4 +6/77 is a HpaIHindII fragment from pAP2L (nucleotides 77-290); GAL4 + 77/165 is a T4 DNA polymerase-repaired NcoI-SmaI fragment from SPRSV AN77 (nucleotides 291-556); GAL4 + 117/165 is a T4 DNA polymerase-repaired NcoI-SmaI fragment from SPRSV AN117 (nucleotides 414-556); and GAL4 + 6/437 is a HpaI-EcoRV fragment of pAP2L, from nucleotide 77 to the EcoRV site in the 3' polylinker.
Cotransfection assays
Cotransfection of HepG2 cells and CAT assays was essentially as described (Baichwal and Tjian 1990) . Transfections contained 5 ~g of reporter construct with either 1 ~g of SPRSV plasmids or 5 ~g of GAL4 plasmids. The amount of DNA per transfection was brought to a total of 15 ~g with puc118 carrier DNA. Transfections were performed at least twice in duplicate.
